Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTEN-UP: Flebavena (diosmin) 1000 mg once daily in chronic venous disease
2017-004804-23Phase 4Completed
- Sponsor
- Krka
- Start
- Jun 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of diosmin in chronic venous disease (CVD) and venous stasis, sponsored by Krka. Primary endpoint: Primary endpoint: proportion of patients with ≥30% reduction in foot pain or NS ≤3 at 12 weeks. Started Jun 2018; status: completed.
02
Drugs
diosmin
03
Conditions
chronic venous disease (CVD)venous stasis
Beyond the preview
Go deeper on 2017-004804-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004804-23.